In addition, the inhibitors (sunitinib and pazopanib) against the tyrosine kinase activity of vascular endothelial growth factor (VEGF) are the most effective first-line options for patients with metastatic ccRCC [30]. Here, VEGFA is linked to nonpapillary renal cell carcinoma.